Dose Modification of Subcutaneous Tocilizumab in Patients with Rheumatoid Arthritis

被引：0
|
作者：
Best, Jennie H. [1 ]
Abbass, Ibrahim [1 ]
Tominna, Lenore [1 ]
Reiss, William [1 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
来源：
AMERICAN HEALTH AND DRUG BENEFITS | 2020年 / 13卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：72 / 73
页数：2
相关论文
共 50 条
  • [1] Dose Modification of Subcutaneous Tocilizumab in Patients with Rheumatoid Arthritis Response
    Punekar, Rajeshwari
    Choi, Jeannie
    Boklage, Susan H.
    Iglesias-Rodriguez, Melitza
    Nola, Kamala
    [J]. AMERICAN HEALTH AND DRUG BENEFITS, 2020, 13 (02): : 73 - 73
  • [2] Real World Dose Modification Patterns of Subcutaneous Tocilizumab Among Patients with Rheumatoid Arthritis
    Punekar, Rajeshwari
    Choi, Jeannie
    Boklage, Susan
    Iglesias-Rodriguez, Melitza
    Nola, Kamala
    [J]. AMERICAN HEALTH AND DRUG BENEFITS, 2019, 12 (08): : 400 - 409
  • [3] Weekly subcutaneous injection of tocilizumab in patients with rheumatoid arthritis
    Ito, Satoshi
    [J]. MODERN RHEUMATOLOGY, 2018, 28 (01) : 17 - 19
  • [4] Utilisation of subcutaneous Tocilizumab in rheumatoid arthritis patients in Grampian
    Philobos, M.
    Davidson, A.
    Dospinescu, P.
    [J]. SCOTTISH MEDICAL JOURNAL, 2019, 64 (03) : NP39 - NP39
  • [5] Subcutaneous tocilizumab for the treatment of rheumatoid arthritis
    Mitchell, Emma
    Jones, Graeme
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2016, 12 (02) : 103 - 114
  • [6] Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis
    Ogata, Atsushi
    Morita, Takayoshi
    Yoshida, Yuji
    Tanaka, Toshio
    [J]. THERAPEUTIC DELIVERY, 2015, 6 (03) : 283 - 295
  • [7] Effect of Dose Escalation of Subcutaneous Tocilizumab on Disease Activity in Patients with Rheumatoid Arthritis in a Randomized Controlled Trial
    Singer, Nora G.
    Mohan, Shalini V.
    Yourish, Jeffrey
    Han, Jian
    Edwardes, Michael
    Michalska, Margaret
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [8] EFFECT OF DOSE ESCALATION OF SUBCUTANEOUS TOCILIZUMAB ON DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A RANDOMIZED CONTROLLED TRIAL
    Singer, N.
    Mohan, S.
    Han, J.
    Edwardes, M.
    Michalska, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1126 - 1126
  • [9] THE EFFECT OF BODYWEIGHT ON RESPONSE TO INTRAVENOUS OR SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Davies, R.
    Vivekanantham, A.
    Lunt, M.
    Watson, K.
    Hyrich, K.
    Bluett, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 981 - 981
  • [10] INDUCTION AND PROGRESSION OF SUBCUTANEOUS NODULOSIS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOCILIZUMAB
    Talotta, R.
    Batticciotto, A.
    Ditto, M. C.
    Gerardi, M. C.
    Ventura, D.
    Puttin, P. Sarzi
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1194 - 1194
12345